	US 11,787,766 B2
	Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof
Lei Jiang, Shanghai (CN); Jianwen Deng, Shanghai (CN); Xiaoli Lu, Shanghai (CN); Ke Shang, Shanghai (CN); Jianyong Shou, Shanghai (CN); Bing Wang, Shanghai (CN); Danyi Wu, Shanghai (CN); Xueli Xu, Shanghai (CN); Yuan Xu, Shanghai (CN); Yi Zhang, Shanghai (CN); and Mingwei Zheng, Shanghai (CN)
Assigned to SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD., Shanghai (CN)
Appl. No. 16/639,949
Filed by SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD., Shanghai (CN)
PCT Filed Aug. 17, 2018, PCT No. PCT/CN2018/101191 § 371(c)(1), (2) Date Jun. 29, 2020, PCT Pub. No. WO2019/034172, PCT Pub. Date Feb. 21, 2019.
Claims priority of application No. 201710712191.8 (CN), filed on Aug. 18, 2017.
Prior Publication US 2020/0392083 A1, Dec. 17, 2020
Int. Cl. C07D 213/69 (2006.01); C07D 213/73 (2006.01); C07D 213/84 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 519/00 (2006.01); A61K 31/137 (2006.01); A61K 31/165 (2006.01); A61K 31/4155 (2006.01); A61K 31/437 (2006.01); A61K 31/44 (2006.01); A61K 31/444 (2006.01); A61K 31/4545 (2006.01); A61K 39/12 (2006.01); A61K 39/245 (2006.01); A61K 39/29 (2006.01); A61K 45/06 (2006.01); C07C 211/03 (2006.01); C07C 223/02 (2006.01); C07D 231/40 (2006.01)

CPC C07D 213/69 (2013.01) [A61K 31/137 (2013.01); A61K 31/165 (2013.01); A61K 31/4155 (2013.01); A61K 31/437 (2013.01); A61K 31/44 (2013.01); A61K 31/444 (2013.01); A61K 31/4545 (2013.01); A61K 39/12 (2013.01); A61K 39/245 (2013.01); A61K 39/29 (2013.01); A61K 45/06 (2013.01); C07C 211/03 (2013.01); C07C 223/02 (2013.01); C07D 213/73 (2013.01); C07D 213/84 (2013.01); C07D 231/40 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 519/00 (2013.01)]

3 Claims

1. A compound selected from the following group, or a stereoisomer, a racemate, or a pharmaceutically acceptable salt thereof,